Alzheimer's Disease and Related Tau Disorders

Image 1

Our Research

The Vossel Laboratory studies mechanisms and novel treatments for epileptic activity and associated memory loss in Alzheimer’s disease. Investigations include cell and molecular, neural network, and behavior relationships in mouse models of Alzheimer’s disease and related dementias, and bridges bench discoveries with human clinical trials.

Image 2

News

Sundowning Occurs in Patients with Alzheimer's and Dementia
Dr. Keith Vossel, Neurologist and Director of the Easton Center, was interviewed in a July 26th Forbes Health article about sundowning and the symptoms that patients with Alzheimer’s disease and dementia may experience.
https://www.forbes.com/health/conditions/sundown-syndrome/

Late Life with Active Lifestyle Lowers the Risk of Dementia
Dr. Keith Vossel, Director of the Easton Center, was quoted in a July 17th Healthline article commented on an observational study that revealed maintaining a socially and mentally active lifestyle in late life reduces the risk of dementia.
https://www.healthline.com/health-news/simple-activities-like-journaling-playing-chess-may-reduce-risk-of-dementia

New Released Information About the Additional Medicare Coverages for Leqembi
Dr. Keith Vossel, neurologist and Director of the Easton Center, was quoted in a Boston Globe’s STAT News article regarding physicians and patients showing interest in learning more about the new Alzheimer’s treatment, Leqembi.
https://epaper.bostonglobe.com/infinity/article_popover_share.aspx?guid=4db484fb-f048-4c14-8be9-607b3be6c8c0

Lecanemab, the New FDA-approved Drug for Patients with Early Alzheimer’s Disease (Segment 2 of 2)
Watch Dr. Keith Vossel's live interview on July 7th, with KCAL-LA Morning News, about the benefits of the treatment, possible side effects, and expected out-of-pocket costs with CMS coverage for patients eligible for Leqembi, a fully FDA-approved Alzheimer’s drug.
https://www.youtube.com/watch?v=NTpY3Qj2rc4

Lecanemab, the New FDA-approved Alzheimer's Drug - What to Know
Watch Dr. Keith Vossel's live interview with Marla Tellez on July 7th, FOX 11 News LA, about the FDA’s full approval of Alzheimer’s drug, Lecanemab, who is eligible, the treatment benefits, side effects, and expected costs with Medicare coverage.
https://www.youtube.com/watch?v=vh2Gz2oUlI8

Future Data Will Determine the Effectiveness of the New Alzheimer’s Drug
Dr. Keith Vossel, Neurologist and Director of the Easton Center, was quoted in a San Francisco Chronicle July 7th article about more observations and real-world data needed to determine the effectiveness of the newly approved Alzheimer’s drug, Leqembi.
https://www.sfchronicle.com/health/article/newly-approved-alzheimer-s-drug-leqembi-means-18188387.php

What Families Can Expect with the New FDA-Approved Alzheimer’s Medication, Leqembi
Watch Dr. Keith Vossel’s exclusive live interview with KNBC-LA, NBC Channel 4 News, about the FDA’s full approval of the Alzheimer’s drug, Lecanemab, marketed as Leqembi, and what it means for families with loved ones in the early stages of Alzheimer’s disease.
https://mms.tveyes.com/MediaCenterPlayer.aspx?u=aHR0cDovL21lZGlhY2
VudGVyLnR2ZXllcy5jb20vZG93bmxvYWRnYXRld2F5LmFzcHg%2FVXNlc
klEPTMzMzAxNiZNRElEPTE5ODMzNTcyJk1EU2VlZD02MjI5JlR5cGU9
TWVkaWE%3D

Lecanemab, the New FDA-approved Drug for Patients with Early Alzheimer’s Disease (Segment 1 of 2)
Watch Dr. Keith Vossel's live interview on July 6th, with KCAL-LA Evening News, about the benefits of the treatment, possible side effects, and expected out-of-pocket costs with CMS coverage for patients eligible for Leqembi, a fully FDA-approved Alzheimer’s drug.
https://www.youtube.com/watch?v=FSw1DtK6TzY